Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 275

1.

Octreotide-mediated tumor cell uptake and intracellular pH-responsive drug delivery of the self-assembly supramolecular nanocarrier.

Niu J, Huang A, Xiao Y, Su Z, Li H, Ping Q, Bao X, Li S, Chen Y, Sun M.

J Drug Target. 2013 May;21(5):415-26. doi: 10.3109/1061186X.2012.757771. Epub 2013 Apr 18.

PMID:
23597028
2.

Octreotide-modified and pH-triggering polymeric micelles loaded with doxorubicin for tumor targeting delivery.

Niu J, Su Z, Xiao Y, Huang A, Li H, Bao X, Li S, Chen Y, Sun M, Ping Q.

Eur J Pharm Sci. 2012 Jan 23;45(1-2):216-26. doi: 10.1016/j.ejps.2011.11.013. Epub 2011 Nov 20.

PMID:
22119655
3.

Effect of octreotide surface density on receptor-mediated endocytosis in vitro and anticancer efficacy of modified nanocarrier in vivo after optimization.

Su Z, Shi Y, Xiao Y, Sun M, Ping Q, Zong L, Li S, Niu J, Huang A, You W, Chen Y, Chen X, Fei J, Tian J.

Int J Pharm. 2013 Apr 15;447(1-2):281-92. doi: 10.1016/j.ijpharm.2013.01.068. Epub 2013 Feb 7.

PMID:
23396258
4.

Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy.

Ko J, Park K, Kim YS, Kim MS, Han JK, Kim K, Park RW, Kim IS, Song HK, Lee DS, Kwon IC.

J Control Release. 2007 Nov 6;123(2):109-15. Epub 2007 Aug 8.

PMID:
17894942
5.

Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles.

Huo M, Zou A, Yao C, Zhang Y, Zhou J, Wang J, Zhu Q, Li J, Zhang Q.

Biomaterials. 2012 Sep;33(27):6393-407. doi: 10.1016/j.biomaterials.2012.05.052. Epub 2012 Jun 14.

PMID:
22704599
6.

Self-assembled nanoparticles based on galactosylated O-carboxymethyl chitosan-graft-stearic acid conjugates for delivery of doxorubicin.

Guo H, Zhang D, Li C, Jia L, Liu G, Hao L, Zheng D, Shen J, Li T, Guo Y, Zhang Q.

Int J Pharm. 2013 Dec 15;458(1):31-8. doi: 10.1016/j.ijpharm.2013.10.020. Epub 2013 Oct 17.

PMID:
24140544
7.

A novel delivery system of doxorubicin with high load and pH-responsive release from the nanoparticles of poly (α,β-aspartic acid) derivative.

Wang X, Wu G, Lu C, Zhao W, Wang Y, Fan Y, Gao H, Ma J.

Eur J Pharm Sci. 2012 Aug 30;47(1):256-64. doi: 10.1016/j.ejps.2012.04.007. Epub 2012 Apr 13.

PMID:
22522116
8.

In vivo studies of octreotide-modified N-octyl-O, N-carboxymethyl chitosan micelles loaded with doxorubicin for tumor-targeted delivery.

Zou A, Chen Y, Huo M, Wang J, Zhang Y, Zhou J, Zhang Q.

J Pharm Sci. 2013 Jan;102(1):126-35. doi: 10.1002/jps.23341. Epub 2012 Oct 16.

PMID:
23073894
9.

Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.

Yu JM, Li YJ, Qiu LY, Jin Y.

J Pharm Pharmacol. 2009 Jun;61(6):713-9. doi: 10.1211/jpp.61.06.0003.

PMID:
19505361
10.

Effect of octreotide-polyethylene glycol(100) monostearate modification on the pharmacokinetics and cellular uptake of nanostructured lipid carrier loaded with hydroxycamptothecine.

Su Z, Niu J, Xiao Y, Ping Q, Sun M, Huang A, You W, Sang X, Yuan D.

Mol Pharm. 2011 Oct 3;8(5):1641-51. doi: 10.1021/mp100463n. Epub 2011 Aug 16.

PMID:
21770405
11.

In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.

Guo H, Zhang D, Li T, Li C, Guo Y, Liu G, Hao L, Shen J, Qi L, Liu X, Luan J, Zhang Q.

J Pharm Sci. 2014 Mar;103(3):987-93. doi: 10.1002/jps.23875. Epub 2014 Jan 24.

PMID:
24549734
12.

Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma.

Shi L, Tang C, Yin C.

Biomaterials. 2012 Oct;33(30):7594-604. doi: 10.1016/j.biomaterials.2012.06.072. Epub 2012 Jul 13.

PMID:
22796165
13.

Tumor-targeting peptide conjugated pH-responsive micelles as a potential drug carrier for cancer therapy.

Wu XL, Kim JH, Koo H, Bae SM, Shin H, Kim MS, Lee BH, Park RW, Kim IS, Choi K, Kwon IC, Kim K, Lee DS.

Bioconjug Chem. 2010 Feb 17;21(2):208-13. doi: 10.1021/bc9005283.

PMID:
20073455
14.

Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.

Han HS, Lee J, Kim HR, Chae SY, Kim M, Saravanakumar G, Yoon HY, You DG, Ko H, Kim K, Kwon IC, Park JC, Park JH.

J Control Release. 2013 Jun 10;168(2):105-14. doi: 10.1016/j.jconrel.2013.02.022. Epub 2013 Mar 6.

PMID:
23474029
15.

pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.

Hu FQ, Zhang YY, You J, Yuan H, Du YZ.

Mol Pharm. 2012 Sep 4;9(9):2469-78. doi: 10.1021/mp300002v. Epub 2012 Aug 7.

PMID:
22827551
16.

Chitosan-g-TPGS nanoparticles for anticancer drug delivery and overcoming multidrug resistance.

Guo Y, Chu M, Tan S, Zhao S, Liu H, Otieno BO, Yang X, Xu C, Zhang Z.

Mol Pharm. 2014 Jan 6;11(1):59-70. doi: 10.1021/mp400514t. Epub 2013 Nov 21.

PMID:
24229050
17.

Preparation of core cross-linked PCL-PEG-PCL micelles for doxorubicin delivery in vitro.

Zhang J, Men K, Gu Y, Wang X, Gou M, Guo G, Luo F, Qian Z.

J Nanosci Nanotechnol. 2011 Jun;11(6):5054-61.

PMID:
21770143
18.

Glycyrrhetinic acid-modified chitosan/poly(ethylene glycol) nanoparticles for liver-targeted delivery.

Tian Q, Zhang CN, Wang XH, Wang W, Huang W, Cha RT, Wang CH, Yuan Z, Liu M, Wan HY, Tang H.

Biomaterials. 2010 Jun;31(17):4748-56. doi: 10.1016/j.biomaterials.2010.02.042. Epub 2010 Mar 19.

PMID:
20303163
19.

Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.

Fan L, Li F, Zhang H, Wang Y, Cheng C, Li X, Gu CH, Yang Q, Wu H, Zhang S.

Biomaterials. 2010 Jul;31(21):5634-42. doi: 10.1016/j.biomaterials.2010.03.066. Epub 2010 Apr 28.

PMID:
20430433
20.

Negative-charge-functionalized mesoporous silica nanoparticles as drug vehicles targeting hepatocellular carcinoma.

Xie M, Xu Y, Shen H, Shen S, Ge Y, Xie J.

Int J Pharm. 2014 Oct 20;474(1-2):223-31. doi: 10.1016/j.ijpharm.2014.08.027. Epub 2014 Aug 19.

PMID:
25149125

Supplemental Content

Support Center